Lung Cancer

Conference Coverage

ELCC: Urine tumor DNA shows high testing promise

Key clinical point: Urine showed potential as a fully noninvasive source for circulating tumor DNA with high testing concordance compared with...


New agent targets EGFR resistance in NSCLC

Key clinical point: AZD9291 was highly active against advanced NSCLC that had mutated to become resistant to treatment with EGFR tyrosine kinase...


Rociletinib active against resistant NSCLC

Key clinical point: Rociletinib exerted prolonged disease control in a phase I study of resistant non–small cell lung cancer. Major finding: After...